Evidence map›Paper›PMID 37207276›Full record

ArticleiScience2023

Dichotomous ovarian cancer-initiating potential of Pax8+ cells revealed by a mouse genetic mosaic model.

Jianhao Zeng, Astrid Catalina Alvarez-Yela, Eli Casarez, Ying Jiang, Lixin Wang, Brianna E Kelly, Taylor Jenkins, Eugene Ke, Kristen A Atkins, Kevin A Janes and 2 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jianhao ZengDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Astrid Catalina Alvarez-YelaDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA.
Eli CasarezDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Ying JiangDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Lixin WangDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA.
Brianna E KellyDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Taylor JenkinsDepartment of Pathology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Eugene KeDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Kristen A AtkinsDepartment of Pathology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Kevin A JanesDepartment of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA.
Jill K Slack-DavisDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
Hui ZongDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, VA 22908, USA.
University of Virginia Health System · USUniversity of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
A premalignant chronology of cell-state variability in basal-like breast cancerR01CA256199 · NCI · UNIVERSITY OF VIRGINIA · PI Andrew Carl Dudley, Kevin A Janes · 2022 to 2026
$3.4M
Interdisciplinary Training in Systems & Biomolecular Data ScienceT32GM145443 · NIGMS · UNIVERSITY OF VIRGINIA · PI Kevin A Janes, Jason Papin · 2022 to 2026
$1.5M
Definition and perturbation of cell-regulatory heterogeneities in solid tumorsR50CA265089 · NCI · UNIVERSITY OF VIRGINIA · PI Lixin Wang · 2021 to 2026
$872k
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA256199NCI NIH HHS R50 CA265089NIGMS NIH HHS T32 GM145443
6 · The paper itself

Abstract

Different cellular compartments within a tissue present distinct cancer-initiating capacities. Current approaches to dissect such heterogeneity require cell-type-specific genetic tools based on a well-understood lineage hierarchy, which are lacking for many tissues. Here, we circumvented this hurdle and revealed the dichotomous capacity of fallopian tube Pax8+ cells in initiating ovarian cancer, utilizing a mouse genetic system that stochastically generates rare GFP-labeled mutant cells. Through clonal analysis and spatial profiling, we determined that only clones founded by rare, stem/progenitor-like Pax8+ cells can expand on acquiring oncogenic mutations whereas vast majority of clones stall immediately. Furthermore, expanded mutant clones undergo further attrition: many turn quiescent shortly after the initial expansion, whereas others sustain proliferation and manifest a bias toward Pax8+ fate, underlying early pathogenesis. Our study showcases the power of genetic mosaic system-based clonal analysis for revealing cellular heterogeneity of cancer-initiating capacity in tissues with limited prior knowledge of lineage hierarchy.

Indexed as

Biological sciencesCancerCell biologyTranscriptomics

Identifiers

PMID37207276
PMCPMC10189502
OpenAlexW4366978450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.